BioTransplant Incorporated

BioTransplant Incorporated develops anti-rejection biotechnologies and organ transplant drugs. It provides monoclonal antibodies as anti-rejection products that allow transplant recipients to accept donor organs, as well as products that increase the organ pool by enabling the transplantation of organs from miniature bodies to human bodies. The company discovers, develops, and commercializes therapies, therapeutic devices, and treatment protocols designed to suppress adverse immune responses and enhance the body's ability to accept donor cells, tissues, and organs.